Boehringer Ingelheim partners with leading scientific institutions in inflammatory bowel disease research

Boehringer IngelheimBoehringer Ingelheim today announced new collaborations with four major scientific partners to enrich research and development of novel therapeutic approaches for patients with inflammatory bowel disease (IBD), including the Icahn School of Medicine at Mount Sinai, Massachusetts General Hospital, Scripps Research Institute and Weill Cornell Medicine. These collaborations aim to identify and validate potential new therapeutic targets as well as identify biomarkers that offer the potential to address the significant unmet medical needs of patients suffering from IBD such as Crohn's disease and ulcerative colitis.

"Academia-industry collaborations are an extraordinarily effective way to advance research and we recognise the importance of joining forces with leading experts to effectively develop innovative therapies," said Clive Wood, senior corporate vice president Discovery Research at Boehringer Ingelheim. "We must gain a better understanding of the mechanisms responsible for the onset and development of IBD-related diseases such as Crohn's disease and ulcerative colitis. With these collaborations, we aim to transform the treatment of immune diseases to ultimately improve lives of patients and those who care for them," he added.

Boehringer Ingelheim scientists from around the world will work hand-in-hand with leading experts at the respective institutions to enhance the speed of cutting-edge research and to foster information sharing. The company will also provide scientific and technology support as well as research funding to the four scientific partners.

Icahn School of Medicine at Mount Sinai - New York (Dr. Sergio Lira, Dr. Miriam Merad, Dr. Andrea Cerutti)
The joint research teams from Mount Sinai and BI will collaborate to interrogate both adaptive and innate immune response mechanisms that may be unique to both Crohn’s disease and ulcerative colitis. This research is expected to provide new insights into IBD pathogenesis and offers unique opportunities for target discovery and biomarker validation.

Massachusetts General Hospital - Boston, Massachusetts (Dr. Frederick Ausubel)
Boehringer Ingelheim's ongoing collaboration with Dr. Frederick Ausubel will leverage the state-of-the-art, high-throughput chemical and genetic screening capabilities to uncover new mechanisms at the host-environment interface that are compromised in patients with IBD.

Scripps Research Institute - La Jolla, California (Dr. Dennis Wolan, Dr. Andrew Su)
The objective of Boehringer Ingelheim's collaboration with Dr. Dennis Wolan is to gain a deeper understanding of the role of specific bacterial enzymes in the onset of ulcerative colitis. Dr. Wolan’s research effort will focus on utilising biophysical, proteomic and chemical biology methods to identify new protein targets involved in the pathology of ulcerative colitis.

Weill Cornell Medicine - New York (Dr. David Artis, Dr. Gregory Sonnenberg)
The research collaboration with Dr. David Artis and Dr. Gregory Sonnenberg at the Jill Roberts Institute for Research in IBD at Weill Cornell Medicine will jointly pursue an integrated pre-clinical and translational research program related to certain defined cellular processes and targets that regulate the maintenance of the gut mucosal barrier in healthy and IBD-affected patients. This work is anticipated to lead to the discovery and validation of new therapeutic modalities and biomarker approaches for IBD.

About IBD
The global prevalence of IBD is increasing, with an estimated 1-1.3 million people in the United States(1) and 2.5-3 million in Europe(2) currently suffering from these diseases and their complications. IBD is a chronic life-long condition with significant health and economic costs. Seventy-five percent of patients with Crohn's disease and 25 percent with ulcerative colitis may require surgery at some point during their lives.(3)

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative "Making more Health" and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.

In 2014, Boehringer Ingelheim achieved net sales of about 13.3 billion euros. R&D expenditure corresponds to 19.9 per cent of its net sales.

1. Centers for Disease Control and Prevention. Inflammatory bowel disease (IBD), http://www.cdc.gov/ibd. Accessed June 08, 2015.
2. Johan Burisch, The burden of inflammatory bowel disease in Europe, Journal of Crohn’s and Colitis, 2013; 7(4):322-334
3. Centers for Disease Control and Prevention. Inflammatory bowel disease (IBD), http://www.cdc.gov/ibd/addressing-ibd.htm. Accessed June 08, 2015.

Most Popular Now

Cancer cells are quick-change artists adapting to …

Until now, researchers have assumed that the growth of solid tumors originates from cancer stem cells characterized by specific surface markers, which develop in a fixed...

Nucala (mepolizumab) gains FDA approval for two ne…

GlaxoSmithKline (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) has approved two new methods for administering Nucala (mepolizumab), an autoinjec...

Jeff Settleman, Ph.D., joins Pfizer to lead Oncolo…

Pfizer Inc. (NYSE: PFE) announced that Jeff Settleman, Ph.D., will join the company as Senior Vice President and Group Head of Oncology Research & Development, leading al...

Full data from CAROLINA® outcome trial support lon…

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced full data from the CAROLINA® trial demonstrating that Trajenta® (linagliptin) did not increase cardio...

Cannabis use among older adults rising rapidly

Cannabis use among older adults is growing faster than any other age group but many report barriers to getting medical marijuana, a lack of communication with their docto...

Cleveland researchers test novel gene therapy for …

A novel gene therapy clinical trial at University Hospitals Seidman Cancer Center and the Case Comprehensive Cancer Center is showing promising results, garnering funding...

Merck pioneers new effort to see MS from the insid…

Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple ...

Bristol-Myers Squibb announces post-closing leader…

Bristol-Myers Squibb Company (NYSE:BMY) today announced the future leadership team of the combined company effective upon completion of the company’s pending merger with ...

Novartis Kisqali significantly extends life in wom…

Novartis announced statistically significant overall survival (OS) results for Kisqali in combination with endocrine therapy[1]. The Phase 3 MONALEESA-7 trial evaluated K...

Amgen joins with community oncology networks for n…

Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiat...

Bayer receives U.S. FDA breakthrough therapy desig…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib (Aliqopa™) for the treatment of adult patie...

Prescription drug costs steadily soar, yet price t…

After reviewing tens of millions of insurance claims for the country’s 49 most popular brand-name prescription drugs, a team from Scripps Research Translational Institute...